Quest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 14.7%, free cash flow grew 5.28% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow DGX
Quest Diagnostics Incorporated (DGX) Return on equity
Quest Diagnostics Incorporated's return on equity over the twelve months to 30 June 2026 was 14.0%, down 0.1 percentage points from fiscal 2025 (14.1%). Over the past ten years it has ranged from 13.2% (fiscal 2024) to 29.9% (fiscal 2021); the current reading is higher than 36% of that period. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 14.1% | 0.93 |
| FY2024 | 13.2% | (0.68) |
| FY2023 | 13.9% | (1.33) |
| FY2022 | 15.2% | (14.73) |
| FY2021 | 29.9% | 7.10 |
| FY2020 | 22.8% | 7.14 |
| FY2019 | 15.7% | 1.27 |
| FY2018 | 14.4% | (1.66) |
| FY2017 | 16.1% | 2.36 |
| FY2016 | 13.7% | (1.91) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| GH Guardant Health, Inc. compare | 171.6% |
| MEDP Medpace Holdings, Inc. compare | 162.2% |
| IDXX IDEXX Laboratories, Inc. compare | 74.2% |
| ILMN Illumina, Inc. compare | 32.4% |
| DGX Quest Diagnostics Incorporated | 14.0% |
| LH Labcorp Holdings Inc. compare | 11.7% |
| RVTY Revvity Inc. compare | 3.21% |
| WAT Waters Corporation compare | 1.92% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on DGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement